TY - JOUR AU - Forman, D. AU - Martel, C. AU - Lacey, C. J. AU - Soerjomataram, I. AU - Lortet-Tieulent, J. AU - Bruni, L. PY - 2012 DA - 2012// TI - Global burden of human papillomavirus and related diseases JO - Vaccine VL - 30 UR - https://doi.org/10.1016/j.vaccine.2012.07.055 DO - 10.1016/j.vaccine.2012.07.055 ID - Forman2012 ER - TY - JOUR AU - Martel, C. AU - Ferlay, J. AU - Franceschi, S. AU - Vignat, J. AU - Bray, F. AU - Forman, D. PY - 2012 DA - 2012// TI - Global burden of cancers attributable to infections in 2008: a review and synthetic analysis JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70137-7 DO - 10.1016/S1470-2045(12)70137-7 ID - Martel2012 ER - TY - JOUR AU - Plummer, M. AU - Martel, C. AU - Vignat, J. AU - Ferlay, J. AU - Bray, F. AU - Franceschi, S. PY - 2016 DA - 2016// TI - Global burden of cancers attributable to infections in 2012: a synthetic analysis JO - Lancet Glob Health VL - 4 UR - https://doi.org/10.1016/S2214-109X(16)30143-7 DO - 10.1016/S2214-109X(16)30143-7 ID - Plummer2016 ER - TY - JOUR AU - Scheurer, M. E. AU - Tortolero-Luna, G. AU - Adler-Storthz, K. PY - 2005 DA - 2005// TI - Human papillomavirus infection: biology, epidemiology, and prevention JO - Int J Gynecol Cancer VL - 15 UR - https://doi.org/10.1111/j.1525-1438.2005.00246.x DO - 10.1111/j.1525-1438.2005.00246.x ID - Scheurer2005 ER - TY - JOUR AU - Moody, C. A. AU - Laimins, L. A. PY - 2010 DA - 2010// TI - Human papillomavirus oncoproteins: pathways to transformation JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2886 DO - 10.1038/nrc2886 ID - Moody2010 ER - TY - JOUR AU - Bodily, J. AU - Laimins, L. A. PY - 2011 DA - 2011// TI - Persistence of human papillomavirus infection: keys to malignant progression JO - Trends Microbiol VL - 19 UR - https://doi.org/10.1016/j.tim.2010.10.002 DO - 10.1016/j.tim.2010.10.002 ID - Bodily2011 ER - TY - JOUR AU - Grabowska, A. K. AU - Riemer, A. B. PY - 2012 DA - 2012// TI - The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system JO - Open Virol J VL - 6 UR - https://doi.org/10.2174/1874357901206010249 DO - 10.2174/1874357901206010249 ID - Grabowska2012 ER - TY - JOUR AU - Howie, H. L. AU - Katzenellenbogen, R. A. AU - Galloway, D. A. PY - 2009 DA - 2009// TI - Papillomavirus E6 proteins JO - Virology VL - 384 UR - https://doi.org/10.1016/j.virol.2008.11.017 DO - 10.1016/j.virol.2008.11.017 ID - Howie2009 ER - TY - JOUR AU - Wise-Draper, T. M. AU - Wells, S. I. PY - 2008 DA - 2008// TI - Papillomavirus E6 and E7 proteins and their cellular targets JO - Front Biosci VL - 13 UR - https://doi.org/10.2741/2739 DO - 10.2741/2739 ID - Wise-Draper2008 ER - TY - JOUR AU - Münger, K. AU - Basile, J. R. AU - Duensing, S. AU - Eichten, A. AU - Gonzalez, S. L. AU - Grace, M. PY - 2001 DA - 2001// TI - Biological activities and molecular targets of the human papillomavirus E7 oncoprotein JO - Oncogene VL - 20 UR - https://doi.org/10.1038/sj.onc.1204860 DO - 10.1038/sj.onc.1204860 ID - Münger2001 ER - TY - JOUR AU - Bernard, H. U. AU - Burk, R. D. AU - Chen, Z. AU - Doorslaer, K. AU - Zur Hausen, H. AU - Villiers, E. M. PY - 2010 DA - 2010// TI - Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments JO - Virology VL - 401 UR - https://doi.org/10.1016/j.virol.2010.02.002 DO - 10.1016/j.virol.2010.02.002 ID - Bernard2010 ER - TY - JOUR AU - Ling, M. AU - Kanayama, M. AU - Roden, R. AU - Wu, T. C. PY - 2000 DA - 2000// TI - Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers JO - J Biomed Sci VL - 7 UR - https://doi.org/10.1007/BF02255810 DO - 10.1007/BF02255810 ID - Ling2000 ER - TY - JOUR AU - Muñoz, N. AU - Bosch, F. X. AU - Sanjosé, S. AU - Herrero, R. AU - Castellsagué, X. AU - Shah, K. V. PY - 2003 DA - 2003// TI - Epidemiologic classification of human papillomavirus types associated with cervical cancer JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa021641 DO - 10.1056/NEJMoa021641 ID - Muñoz2003 ER - TY - JOUR AU - Schiffman, M. AU - Clifford, G. AU - Buonaguro, F. M. PY - 2009 DA - 2009// TI - Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline JO - Infect Agent Cancer VL - 4 UR - https://doi.org/10.1186/1750-9378-4-8 DO - 10.1186/1750-9378-4-8 ID - Schiffman2009 ER - TY - JOUR AU - Guan, P. AU - Howell-Jones, R. AU - Li, N. AU - Bruni, L. AU - Sanjosé, S. AU - Franceschi, S. PY - 2012 DA - 2012// TI - Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.27485 DO - 10.1002/ijc.27485 ID - Guan2012 ER - TY - JOUR AU - Chaturvedi, A. K. PY - 2010 DA - 2010// TI - Beyond cervical cancer: burden of other HPV-related cancers among men and women JO - J Adolesc Health VL - 46 UR - https://doi.org/10.1016/j.jadohealth.2010.01.016 DO - 10.1016/j.jadohealth.2010.01.016 ID - Chaturvedi2010 ER - TY - JOUR PY - 2007 DA - 2007// TI - Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa061741 DO - 10.1056/NEJMoa061741 ID - ref17 ER - TY - JOUR PY - 2010 DA - 2010// TI - FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) JO - MMWR Morb Mortal Wkly Rep VL - 59 ID - ref18 ER - TY - JOUR AU - Petrosky, E. AU - Bocchini, J. A. AU - Hariri, S. AU - Chesson, H. AU - Curtis, C. R. AU - Saraiya, M. PY - 2015 DA - 2015// TI - Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices JO - MMWR Morb Mortal Wkly Rep VL - 64 ID - Petrosky2015 ER - TY - JOUR AU - Stern, P. L. AU - Burg, S. H. AU - Hampson, I. N. AU - Broker, T. R. AU - Fiander, A. AU - Lacey, C. J. PY - 2012 DA - 2012// TI - Therapy of human papillomavirus-related disease JO - Vaccine VL - 30 UR - https://doi.org/10.1016/j.vaccine.2012.05.091 DO - 10.1016/j.vaccine.2012.05.091 ID - Stern2012 ER - TY - JOUR AU - Milinovic, D. AU - Kalafatic, D. AU - Babic, D. AU - Oreskovic, L. B. AU - Grsic, H. L. AU - Oreskovic, S. PY - 2009 DA - 2009// TI - Minimally invasive therapy of cervical intraepithelial neoplasia for fertility preservation JO - Pathol Oncol Res VL - 15 UR - https://doi.org/10.1007/s12253-009-9148-y DO - 10.1007/s12253-009-9148-y ID - Milinovic2009 ER - TY - JOUR PY - 2017 DA - 2017// TI - Integrated genomic and molecular characterization of cervical cancer JO - Nature VL - 541 UR - https://doi.org/10.1038/nature20805 DO - 10.1038/nature20805 ID - ref22 ER - TY - JOUR AU - Rose, P. G. PY - 2003 DA - 2003// TI - Combined-modality therapy of locally advanced cervical cancer JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.01.222 DO - 10.1200/JCO.2003.01.222 ID - Rose2003 ER - TY - JOUR AU - Moore, D. H. AU - Blessing, J. A. AU - McQuellon, R. P. AU - Thaler, H. T. AU - Cella, D. AU - Benda, J. PY - 2004 DA - 2004// TI - Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.04.170 DO - 10.1200/JCO.2004.04.170 ID - Moore2004 ER - TY - JOUR AU - Monk, B. J. AU - Sill, M. W. AU - McMeekin, D. S. AU - Cohn, D. E. AU - Ramondetta, L. M. AU - Boardman, C. H. PY - 2009 DA - 2009// TI - Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.21.8909 DO - 10.1200/JCO.2009.21.8909 ID - Monk2009 ER - TY - JOUR AU - Tewari, K. S. AU - Sill, M. W. AU - Long, H. J. AU - Penson, R. T. AU - Huang, H. AU - Ramondetta, L. M. PY - 2014 DA - 2014// TI - Improved survival with bevacizumab in advanced cervical cancer JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1309748 DO - 10.1056/NEJMoa1309748 ID - Tewari2014 ER - TY - JOUR AU - Gill, B. S. AU - Bernard, M. E. AU - Lin, J. F. AU - Balasubramani, G. K. AU - Rajagopalan, M. S. AU - Sukumvanich, P. PY - 2015 DA - 2015// TI - Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis JO - Gynecol Oncol VL - 137 UR - https://doi.org/10.1016/j.ygyno.2015.03.056 DO - 10.1016/j.ygyno.2015.03.056 ID - Gill2015 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Vulvar cancer (squamous cell carcinoma). Version 1.2017. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 30 Nov 2016. UR - https://www.nccn.org/professionals/physician_gls/f_guidelines.asp ID - ref28 ER - TY - CHAP AU - Eifel, P. J. AU - Berek, J. S. AU - Markman, M. A. ED - DeVita, V. T. ED - Lawrence, T. S. ED - Rosenberg, S. A. PY - 2011 DA - 2011// TI - Cancer of the cervix, vagina, and vulva BT - DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology PB - Wilkins CY - Philadelphia, Pa ID - Eifel2011 ER - TY - JOUR AU - Samant, R. AU - Lau, B. AU - Choan, E. AU - Le, T. AU - Tam, T. PY - 2007 DA - 2007// TI - Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum JO - Int J Radiat Oncol Biol Phys VL - 69 UR - https://doi.org/10.1016/j.ijrobp.2007.04.015 DO - 10.1016/j.ijrobp.2007.04.015 ID - Samant2007 ER - TY - JOUR AU - Olthof, N. C. AU - Straetmans, J. M. AU - Snoeck, R. AU - Ramaekers, F. C. AU - Kremer, B. AU - Speel, E. J. PY - 2012 DA - 2012// TI - Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? JO - Rev Med Virol VL - 22 UR - https://doi.org/10.1002/rmv.714 DO - 10.1002/rmv.714 ID - Olthof2012 ER - TY - JOUR AU - Chaturvedi, A. K. AU - Engels, E. A. AU - Pfeiffer, R. M. AU - Hernandez, B. Y. AU - Xiao, W. AU - Kim, E. PY - 2011 DA - 2011// TI - Human papillomavirus and rising oropharyngeal cancer incidence in the United States JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.36.4596 DO - 10.1200/JCO.2011.36.4596 ID - Chaturvedi2011 ER - TY - JOUR AU - Varier, I. AU - Keeley, B. R. AU - Krupar, R. AU - Patsias, A. AU - Dong, J. AU - Gupta, N. PY - 2016 DA - 2016// TI - Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes JO - Head Neck VL - 38 UR - https://doi.org/10.1002/hed.24442 DO - 10.1002/hed.24442 ID - Varier2016 ER - TY - JOUR AU - Truong Lam, M. AU - O'Sullivan, B. AU - Gullane, P. AU - Huang, S. H. PY - 2016 DA - 2016// TI - Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma JO - Laryngoscope VL - 126 UR - https://doi.org/10.1002/lary.25985 DO - 10.1002/lary.25985 ID - Truong Lam2016 ER - TY - JOUR AU - Cracchiolo, J. R. AU - Baxi, S. S. AU - Morris, L. G. AU - Ganly, I. AU - Patel, S. G. AU - Cohen, M. A. PY - 2016 DA - 2016// TI - Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base JO - Cancer VL - 122 UR - https://doi.org/10.1002/cncr.29938 DO - 10.1002/cncr.29938 ID - Cracchiolo2016 ER - TY - JOUR AU - Ferris, R. L. AU - Blumenschein, G. AU - Fayette, J. AU - Guigay, J. AU - Colevas, A. D. AU - Licitra, L. PY - 2016 DA - 2016// TI - Nivolumab for recurrent squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1602252 DO - 10.1056/NEJMoa1602252 ID - Ferris2016 ER - TY - JOUR AU - Goldstone, S. E. AU - Kawalek, A. Z. AU - Huyett, J. W. PY - 2005 DA - 2005// TI - Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions JO - Dis Colon rectum VL - 48 UR - https://doi.org/10.1007/s10350-004-0889-0 DO - 10.1007/s10350-004-0889-0 ID - Goldstone2005 ER - TY - JOUR AU - Leon, O. AU - Guren, M. G. AU - Radu, C. AU - Gunnlaugsson, A. AU - Johnsson, A. PY - 2015 DA - 2015// TI - Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.08.029 DO - 10.1016/j.ejca.2015.08.029 ID - Leon2015 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Anal carcinoma. Version 1.2017. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 30 Nov 2016. UR - https://www.nccn.org/professionals/physician_gls/f_guidelines.asp ID - ref39 ER - TY - JOUR AU - Lorenzo, G. AU - Buonerba, C. AU - Ferro, M. AU - Calderoni, G. AU - Bozza, G. AU - Federico, P. PY - 2015 DA - 2015// TI - The epidermal growth factor receptors as biological targets in penile cancer JO - Expert Opin Biol Ther VL - 15 UR - https://doi.org/10.1517/14712598.2015.993377 DO - 10.1517/14712598.2015.993377 ID - Lorenzo2015 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Penile cancer. Version 2. 2016. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 30 Nov 2016. UR - https://www.nccn.org/professionals/physician_gls/f_guidelines.asp ID - ref41 ER - TY - JOUR AU - Poelgeest, M. I. AU - Seters, M. AU - Beurden, M. AU - Kwappenberg, K. M. AU - Heijmans-Antonissen, C. AU - Drijfhout, J. W. PY - 2005 DA - 2005// TI - Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-05-0616 DO - 10.1158/1078-0432.CCR-05-0616 ID - Poelgeest2005 ER - TY - JOUR AU - Kobayashi, A. AU - Weinberg, V. AU - Darragh, T. AU - Smith-McCune, K. PY - 2008 DA - 2008// TI - Evolving immunosuppressive microenvironment during human cervical carcinogenesis JO - Mucosal Immunol VL - 1 UR - https://doi.org/10.1038/mi.2008.33 DO - 10.1038/mi.2008.33 ID - Kobayashi2008 ER - TY - JOUR AU - Kenter, G. G. AU - Welters, M. J. AU - Valentijn, A. R. AU - Lowik, M. J. AU - Berends-van der Meer, D. M. AU - Vloon, A. P. PY - 2008 DA - 2008// TI - Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1881 DO - 10.1158/1078-0432.CCR-07-1881 ID - Kenter2008 ER - TY - JOUR AU - Palefsky, J. M. AU - Berry, J. M. AU - Jay, N. AU - Krogstad, M. AU - Costa, M. AU - Darragh, T. M. PY - 2006 DA - 2006// TI - A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals JO - AIDS VL - 20 UR - https://doi.org/10.1097/01.aids.0000226955.02719.26 DO - 10.1097/01.aids.0000226955.02719.26 ID - Palefsky2006 ER - TY - JOUR AU - Frazer, I. H. AU - Quinn, M. AU - Nicklin, J. L. AU - Tan, J. AU - Perrin, L. C. AU - Ng, P. PY - 2004 DA - 2004// TI - Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia JO - Vaccine VL - 23 UR - https://doi.org/10.1016/j.vaccine.2004.05.013 DO - 10.1016/j.vaccine.2004.05.013 ID - Frazer2004 ER - TY - JOUR AU - Roman, L. D. AU - Wilczynski, S. AU - Muderspach, L. I. AU - Burnett, A. F. AU - O'Meara, A. AU - Brinkman, J. A. PY - 2007 DA - 2007// TI - A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia JO - Gynecol Oncol VL - 106 UR - https://doi.org/10.1016/j.ygyno.2007.05.038 DO - 10.1016/j.ygyno.2007.05.038 ID - Roman2007 ER - TY - JOUR AU - Welters, M. J. AU - Kenter, G. G. AU - Piersma, S. J. AU - Vloon, A. P. AU - Löwik, M. J. AU - Berends-van der Meer, D. M. PY - 2008 DA - 2008// TI - Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1880 DO - 10.1158/1078-0432.CCR-07-1880 ID - Welters2008 ER - TY - JOUR AU - Trimble, C. L. AU - Peng, S. AU - Kos, F. AU - Gravitt, P. AU - Viscidi, R. AU - Sugar, E. PY - 2009 DA - 2009// TI - A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3 JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1725 DO - 10.1158/1078-0432.CCR-08-1725 ID - Trimble2009 ER - TY - JOUR AU - Santin, A. D. AU - Bellone, S. AU - Palmieri, M. AU - Zanolini, A. AU - Ravaggi, A. AU - Siegel, E. R. PY - 2008 DA - 2008// TI - Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial JO - J Virol VL - 82 UR - https://doi.org/10.1128/JVI.02343-07 DO - 10.1128/JVI.02343-07 ID - Santin2008 ER - TY - JOUR AU - Ferrara, A. AU - Nonn, M. AU - Sehr, P. AU - Schreckenberger, C. AU - Pawlita, M. AU - Dürst, M. PY - 2003 DA - 2003// TI - Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients JO - J Cancer Res Clin Oncol VL - 129 UR - https://doi.org/10.1007/s00432-003-0463-5 DO - 10.1007/s00432-003-0463-5 ID - Ferrara2003 ER - TY - JOUR AU - Stevanović, S. AU - Draper, L. M. AU - Langhan, M. M. AU - Campbell, T. E. AU - Kwong, M. L. AU - Wunderlich, J. R. PY - 2015 DA - 2015// TI - Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.9093 DO - 10.1200/JCO.2014.58.9093 ID - Stevanović2015 ER - TY - JOUR AU - García-Hernández, E. AU - González-Sánchez, J. L. AU - Andrade-Manzano, A. AU - Contreras, M. L. AU - Padilla, S. AU - Guzmán, C. C. PY - 2006 DA - 2006// TI - Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine JO - Cancer Gene Ther VL - 13 UR - https://doi.org/10.1038/sj.cgt.7700937 DO - 10.1038/sj.cgt.7700937 ID - García-Hernández2006 ER - TY - JOUR AU - Davidson, E. J. AU - Faulkner, R. L. AU - Sehr, P. AU - Pawlita, M. AU - Smyth, L. J. AU - Burt, D. J. PY - 2004 DA - 2004// TI - Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) JO - Vaccine VL - 22 UR - https://doi.org/10.1016/j.vaccine.2004.01.049 DO - 10.1016/j.vaccine.2004.01.049 ID - Davidson2004 ER - TY - JOUR AU - Zenewicz, L. A. AU - Shen, H. PY - 2007 DA - 2007// TI - Innate and adaptive immune responses to Listeria monocytogenes: a short overview JO - Microbes Infect VL - 9 UR - https://doi.org/10.1016/j.micinf.2007.05.008 DO - 10.1016/j.micinf.2007.05.008 ID - Zenewicz2007 ER - TY - JOUR AU - Pan, Z. K. AU - Ikonomidis, G. AU - Lazenby, A. AU - Pardoll, D. AU - Paterson, Y. PY - 1995 DA - 1995// TI - A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours JO - Nat Med VL - 1 UR - https://doi.org/10.1038/nm0595-471 DO - 10.1038/nm0595-471 ID - Pan1995 ER - TY - CHAP AU - Rothman, J. AU - Wallecha, A. AU - Maciag, P. C. AU - Rivera, S. AU - Shahabi, V. AU - Paterson, Y. ED - Fialho, A. M. ED - Chakrabarty, A. PY - 2010 DA - 2010// TI - The use of living Listeria monocytogenes as an active immunotherapy for the treatment of cancer BT - Emerging cancer therapy: microbial approaches and biotechnological tools PB - Sons, Inc. CY - New York UR - https://doi.org/10.1002/9780470626528.ch2 DO - 10.1002/9780470626528.ch2 ID - Rothman2010 ER - TY - JOUR AU - Campisi, L. AU - Soudja, S. M. AU - Cazareth, J. AU - Bassand, D. AU - Lazzari, A. AU - Brau, F. PY - 2011 DA - 2011// TI - Splenic CD8α+ dendritic cells undergo rapid programming by cytosolic bacteria and inflammation to induce protective CD8+ T-cell memory JO - Eur J Immunol VL - 41 UR - https://doi.org/10.1002/eji.201041036 DO - 10.1002/eji.201041036 ID - Campisi2011 ER - TY - JOUR AU - Shahabi, V. AU - Reyes-Reyes, M. AU - Wallecha, A. AU - Rivera, S. AU - Paterson, Y. AU - Maciag, P. PY - 2008 DA - 2008// TI - Development of a Listeria monocytogenes based vaccine against prostate cancer JO - Cancer Immunol Immunother VL - 57 UR - https://doi.org/10.1007/s00262-008-0463-z DO - 10.1007/s00262-008-0463-z ID - Shahabi2008 ER - TY - JOUR AU - Wallecha, A. AU - French, C. AU - Petit, R. AU - Singh, R. AU - Amin, A. AU - Rothman, J. PY - 2012 DA - 2012// TI - Lm-LLO-based immunotherapies and HPV-associated disease JO - J Oncol VL - 2012 UR - https://doi.org/10.1155/2012/542851 DO - 10.1155/2012/542851 ID - Wallecha2012 ER - TY - JOUR AU - Maciag, P. C. AU - Radulovic, S. AU - Rothman, J. PY - 2009 DA - 2009// TI - The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix JO - Vaccine VL - 27 UR - https://doi.org/10.1016/j.vaccine.2009.04.041 DO - 10.1016/j.vaccine.2009.04.041 ID - Maciag2009 ER - TY - JOUR AU - Heras, A. AU - Cain, R. J. AU - Bielecka, M. K. AU - Vázquez-Boland, J. A. PY - 2011 DA - 2011// TI - Regulation of Listeria virulence: PrfA master and commander JO - Curr Opin Microbiol VL - 14 UR - https://doi.org/10.1016/j.mib.2011.01.005 DO - 10.1016/j.mib.2011.01.005 ID - Heras2011 ER - TY - STD TI - Huh WK, Brady WE, Moore KN, Lankes HA, Monk BJ, Aghajanian C, et al. A phase 2 study of live-attenuated Listeria monocytogenes cancer immunotherapy (ADXS11–001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). J Clin Oncol. 2014;32(suppl): abstract TPS5617. ID - ref63 ER - TY - STD TI - Ghamande SA, Dobbins R, Marshall L, Wheatley D, Price C, Mauro DJ, et al. Phase I study evaluating high dose ADXS11–001 treatment in women with carcinoma of the cervix. J Clin Oncol. 2015;33(suppl): abstract TPS3096. ID - ref64 ER - TY - STD TI - Petit RG, Mehta A, Jain M, Gupta S, Nagarkar R, Kumar V, et al. ADXS11–001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer. J Immunother Cancer. 2014;2(suppl 3): abstract P92. ID - ref65 ER - TY - STD TI - Herzog T, Backes FJ, Copeland L, Estevez Diz MD, Hare TW, Huh W, et al. AIM2CERV: a randomized phase 3 study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC). J Immunother Cancer. 2016;4(suppl 1): abstract P140. ID - ref66 ER - TY - STD TI - Cohen EE, Moore KN, Slomovitz BM, Chung CH, Anderson ML, Morris SR, et al. Phase I/II study of ADXS11–001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. J Immunother Cancer. 2015;3(suppl 2): abstract P147. ID - ref67 ER - TY - STD TI - Krupar R, Imai N, Miles B, Genden E, Misiukiewicz K, Saegner Y, et al. HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11–001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity. Cancer Res. 2016;76(14 suppl): abstract LB-095. ID - ref68 ER - TY - STD TI - U.S. National Institutes of Health. ClinicalTrials.gov. Safety study of recombinant Listeria monocytogenes (Lm) based vaccine virus vaccine to treat oropharyngeal cancer (REALISTIC). https://clinicaltrials.gov/ct2/show/NCT01598792. Accessed 30 Nov 2016. UR - https://clinicaltrials.gov/ct2/show/NCT01598792 ID - ref69 ER - TY - STD TI - U.S. National Institutes of Health. ClinicalTrials.gov. A phase I/II evaluation of ADXS11–001, mitomycin, 5-fluorouracil (5-FU) and IMRT for anal cancer (276). https://clinicaltrials.gov/ct2/show/NCT01671488. Accessed 30 Nov 2016. UR - https://clinicaltrials.gov/ct2/show/NCT01671488 ID - ref70 ER - TY - STD TI - Fakih M, O'Neil BH, Chiorean EG, Hochster HS, Chan E, Mauro D, et al. Phase II study of ADXS11–001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal. J Clin Oncol. 2016;34(4 suppl): abstract TPS786. ID - ref71 ER - TY - JOUR AU - Guo, T. AU - Rettig, E. AU - Fakhry, C. PY - 2016 DA - 2016// TI - Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma JO - Oral Oncol VL - 52 UR - https://doi.org/10.1016/j.oraloncology.2015.10.016 DO - 10.1016/j.oraloncology.2015.10.016 ID - Guo2016 ER - TY - JOUR AU - Chaturvedi, A. K. AU - Engels, E. A. AU - Pfeiffer, R. M. AU - Hernandez, B. Y. AU - Xiao, W. AU - Kim, E. PY - 2011 DA - 2011// TI - Human papillomavirus and rising oropharyngeal cancer incidence in the United States JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.36.4596 DO - 10.1200/JCO.2011.36.4596 ID - Chaturvedi2011 ER - TY - JOUR AU - Gillison, M. L. AU - Chaturvedi, A. K. AU - Anderson, W. F. AU - Fakhry, C. PY - 2015 DA - 2015// TI - Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.6995 DO - 10.1200/JCO.2015.61.6995 ID - Gillison2015 ER - TY - JOUR AU - Geynisman, D. M. AU - Chien, C. R. AU - Smieliauskas, F. AU - Shen, C. AU - Tina Shih, Y. C. PY - 2014 DA - 2014// TI - Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review JO - Hum Vaccin Immunother VL - 10 UR - https://doi.org/10.4161/hv.29407 DO - 10.4161/hv.29407 ID - Geynisman2014 ER - TY - JOUR AU - Darden, P. M. AU - Thompson, D. M. AU - Roberts, J. R. AU - Hale, J. J. AU - Pope, C. AU - Naifeh, M. PY - 2013 DA - 2013// TI - Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010 JO - Pediatrics VL - 131 UR - https://doi.org/10.1542/peds.2012-2384 DO - 10.1542/peds.2012-2384 ID - Darden2013 ER -